Anzeige
❌
Mehr »
Mittwoch, 18.11.2026 - Börsentäglich über 12.000 News
Folge dem Geld: Methan im Fokus der COP31!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
LO

WKN: A42JCL | ISIN: US54303L3024 | Ticker:
NASDAQ
17.11.26 | 21:52
2,110 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
LONGEVERON INC Chart 1 Jahr
5-Tage-Chart
LONGEVERON INC 5-Tage-Chart

Aktuelle News zur LONGEVERON Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoLongeveron GAAP EPS of -$1.91 misses by $0.21, revenue of $0.12M misses by $0.68M1
LONGEVERON Aktie jetzt für 0€ handeln
DoLongeveron Announces 2026 Third Quarter Financial Results and Provides Business Update1
DoLongeveron Inc. - 8-K, Current Report-
DoLongeveron Inc. - 10-Q, Quarterly Report-
05.11.Longeveron Inc. - 8-K, Current Report2
28.10.Longeveron Announces Engagement of Lucid Capital Markets2
26.10.Longeveron Inc. - 8-K, Current Report3
26.10.Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)6
14.10.Longeveron Inc. - 8-K, Current Report1
23.09.Longeveron Inc. - 8-K, Current Report2
23.09.Longeveron (LGVN) Heart Treatment Falls Short. Can a Strategic Review Preserve Value?1
17.09.Morning Market Movers: Aethlon Medical, CID HoldCo, Longeveron, Delixy See Big Swings949OTTAWA (dpa-AFX) - At 8:50 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening...
► Artikel lesen
17.09.Longeveron's phase 2b stem cell flop spurs cost cutting, exploration of 'all options'12
17.09.Longeveron (LGVN) Shares Slide 59% After Hours: Here's Why5
16.09.Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)256Company Announces Exploration of All Options to Maximize Shareholder Value The top line results showed that the ELPIS II trial did not meet its primary endpoint of improvement in right ventricular...
► Artikel lesen
14.09.Longeveron Inc. - 8-K, Current Report2
24.08.Longeveron plans 1-for-10 reverse stock split to regain Nasdaq minimum bid-price compliance1
24.08.Longeveron Announces 1-for-10 Reverse Stock Split454MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related...
► Artikel lesen
19.08.Nirav Jhaveri wird neuer CFO bei Longeveron1
19.08.Longeveron Inc. - 8-K, Current Report4
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1